


Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.02.2013
- 2 As per the audited Balance Sheet as at 31st March, 2011, the Company's Net Worth had been completely eroded. Therefore, as required under Section 15 (1) of the Sick Industrial Companies (Special Provisions) Act, 1985, the company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR) for measures to be determined with respect to the company. Accordingly, the company is registered with the BIFR.
- 3 The company had issued 17,500,000 convertible warrants to Mr.Mark Saldanha, Promoter of the Company, on preferential Basis. Mr.Mark Saldanha has exercised his right of conversion of the said warrants into equity shares. Accordingly the company has on 14.12.2012 issued and allotted 17,500,000 equity shares of ₹ 1/- Each to Mr.Mark Saldanha in conversion of the warrants. Consequently, the company's Issued,Subscribed Paid up Equity Share Capital has increased from 367,807,204 equity shares of ₹ 1/- each to 385,307,204 equity shares of ₹ 1/- each effective from 14.12.2012.
- 4 The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 5 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 6 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 7 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 8 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

Place: Mumbai.
Date: 14.02.2013

For MARKSANS PHARMA LIMITED


MARK SALDANHA
Managing Director.

